This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zenklusen, J. C. Articles by Conti, C. J. Search for Related Content PubMed PubMed Citation Articles by Zenklusen, J. C. Articles by Conti, C. J.

Loss of Heterozygosity in Human Primary Prostate Carcinomas: A Possible Tumor Suppressor Gene at 7q31.1¹

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 [J. C. Z., J. C. T., C. J. C.], and Department of Pathology [P. T.] and Division of Laboratory Medicine [J. K.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

We studied loss of heterozygosity (LOH) on human chromosome 7q to determine the location of a putative tumor suppressor gene (TSG) in human primary prostate carcinomas. Samples were obtained from 16 primary prostate carcinomas surgically removed from patients at The University of Texas M. D. Anderson Cancer Center. Paired normal and tumor DNAs were used as template for PCR amplification of a set of 14 CA microsatellite repeats on 7q21-qter. Twelve of 16 cases studied had LOH at one or more loci on 7q. Eighty-three percent LOH (five of six informative cases) was detected with D7S522 at 7q31.1-7q31.2. Percentage of LOH was normally distributed around D7S522. The high incidence of LOH in primary prostate carcinomas suggests that there is a TSG relevant to the development of prostate cancers at 7q31.1-31.2, confirming our previous functional evidence for a TSG at this location. Further research needs to be conducted to establish the identity and function of this putative TSG.

¹ Supported by National Cancer Institute Grant CA53123.

² To whom correspondence should be addressed.

Received 9/ 6/94. Accepted 11/ 2/94.

This article has been cited by other articles:

				C. Bianco, L. Strizzi, M. Mancino, K. Watanabe, M. Gonzales, S. Hamada, A. Raafat, L. Sahlah, C. Chang, F. Sotgia, et al. Regulation of Cripto-1 Signaling and Biological Activity by Caveolin-1 in Mammary Epithelial Cells Am. J. Pathol., February 1, 2008; 172(2): 345 - 357. [Abstract] [Full Text] [PDF]

				T. Li, F. Sotgia, M. A. Vuolo, M. Li, W. C. Yang, R. G. Pestell, J. A. Sparano, and M. P. Lisanti Caveolin-1 Mutations in Human Breast Cancer: Functional Association with Estrogen Receptor {alpha}-Positive Status Am. J. Pathol., June 1, 2006; 168(6): 1998 - 2013. [Abstract] [Full Text] [PDF]

				F. Sotgia, T. M. Williams, W. Schubert, F. Medina, C. Minetti, R. G. Pestell, and M. P. Lisanti Caveolin-1 Deficiency (-/-) Conveys Premalignant Alterations in Mammary Epithelia, with Abnormal Lumen Formation, Growth Factor Independence, and Cell Invasiveness Am. J. Pathol., January 1, 2006; 168(1): 292 - 309. [Abstract] [Full Text] [PDF]

				T. M. Williams and M. P. Lisanti Caveolin-1 in oncogenic transformation, cancer, and metastasis Am J Physiol Cell Physiol, March 1, 2005; 288(3): C494 - C506. [Abstract] [Full Text] [PDF]

				A. W. Cohen, R. Hnasko, W. Schubert, and M. P. Lisanti Role of Caveolae and Caveolins in Health and Disease Physiol Rev, October 1, 2004; 84(4): 1341 - 1379. [Abstract] [Full Text] [PDF]

				F. Capozza, T. M. Williams, W. Schubert, S. McClain, B. Bouzahzah, F. Sotgia, and M. P. Lisanti Absence of Caveolin-1 Sensitizes Mouse Skin to Carcinogen-Induced Epidermal Hyperplasia and Tumor Formation Am. J. Pathol., June 1, 2003; 162(6): 2029 - 2039. [Abstract] [Full Text] [PDF]

				T. M. Williams, M. W.-C. Cheung, D. S. Park, B. Razani, A. W. Cohen, W. J. Muller, D. Di Vizio, N. G. Chopra, R. G. Pestell, and M. P. Lisanti Loss of Caveolin-1 Gene Expression Accelerates the Development of Dysplastic Mammary Lesions in Tumor-Prone Transgenic Mice Mol. Biol. Cell, March 1, 2003; 14(3): 1027 - 1042. [Abstract] [Full Text] [PDF]

				H. Lee, D. S. Park, B. Razani, R. G. Russell, R. G. Pestell, and M. P. Lisanti Caveolin-1 Mutations (P132L and Null) and the Pathogenesis of Breast Cancer : Caveolin-1 (P132L) Behaves in a Dominant-Negative Manner and Caveolin-1 (-/-) Null Mice Show Mammary Epithelial Cell Hyperplasia Am. J. Pathol., October 1, 2002; 161(4): 1357 - 1369. [Abstract] [Full Text] [PDF]

				B. Razani, S. E. Woodman, and M. P. Lisanti Caveolae: From Cell Biology to Animal Physiology Pharmacol. Rev., September 1, 2002; 54(3): 431 - 467. [Abstract] [Full Text] [PDF]

				K. Wiechen, L. Diatchenko, A. Agoulnik, K. M. Scharff, H. Schober, K. Arlt, B. Zhumabayeva, P. D. Siebert, M. Dietel, R. Schafer, et al. Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene Am. J. Pathol., November 1, 2001; 159(5): 1635 - 1643. [Abstract] [Full Text] [PDF]

				H. H. Shih, M. Xiu, S. P. Berasi, E. M. Sampson, A. Leiter, K. E. Paulson, and A. S. Yee HMG Box Transcriptional Repressor HBP1 Maintains a Proliferation Barrier in Differentiated Liver Tissue Mol. Cell. Biol., September 1, 2001; 21(17): 5723 - 5732. [Abstract] [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				B Razani, A Schlegel, and M. Lisanti Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy J. Cell Sci., January 6, 2000; 113(12): 2103 - 2109. [Abstract] [PDF]

				Loss of Heterozygosity of the Long Arm of Chromosome 7 in Follicular and Anaplastic Thyroid Cancer, but Not in Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3235 - 3240. [Abstract] [Full Text] [PDF]

				S. Knuutila, Y. Aalto, K. Autio, A.-M. Bjorkqvist, W.'e. El-Rifai, S. Hemmer, T. Huhta, E. Kettunen, S. Kiuru-Kuhlefelt, M. L. Larramendy, et al. DNA Copy Number Losses in Human Neoplasms Am. J. Pathol., September 1, 1999; 155(3): 683 - 694. [Abstract] [Full Text] [PDF]

				K. Das, R. Y. Lewis, P. E. Scherer, and M. P. Lisanti The Membrane-spanning Domains of Caveolins-1 and -2 Mediate the Formation of Caveolin Hetero-oligomers. IMPLICATIONS FOR THE ASSEMBLY OF CAVEOLAE MEMBRANES IN VIVO J. Biol. Chem., June 25, 1999; 274(26): 18721 - 18728. [Abstract] [Full Text] [PDF]

				D. Li, X. L. Sun, B. Casto, J. Fang, K. Theil, R. Glaser, and G. Milo Epstein-Barr virus growth-transformed cells are converted to malignancy following transfection of a 1.3-kb CATR1 antisense construct independent of a change in the level of c-myc expression followed by a 8;14 chromosomal translocation PNAS, April 28, 1998; 95(9): 4894 - 4899. [Abstract] [Full Text] [PDF]

				H. Liang, J. Fairman, D. F. Claxton, P. C. Nowell, E. D. Green, and L. Nagarajan Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: Evidence for multiple critical loci PNAS, March 31, 1998; 95(7): 3781 - 3785. [Abstract] [Full Text] [PDF]

				J C Zenklusen, L V Rodriguez, M LaCava, Z Wang, L S Goldstein, and C J Conti Novel susceptibility locus for mouse hepatomas: evidence for a conserved tumor suppressor gene. Genome Res., November 1, 1996; 6(11): 1070 - 1076. [Abstract] [PDF]

				B. Razani, J. A. Engelman, X. B. Wang, W. Schubert, X. L. Zhang, C. B. Marks, F. Macaluso, R. G. Russell, M. Li, R. G. Pestell, et al. Caveolin-1 Null Mice Are Viable but Show Evidence of Hyperproliferative and Vascular Abnormalities J. Biol. Chem., October 5, 2001; 276(41): 38121 - 38138. [Abstract] [Full Text] [PDF]